

Spina Bifida In Utero Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/S145F0215EC8EN.html>

Date: May 2024

Pages: 129

Price: US\$ 6,499.00 (Single User License)

ID: S145F0215EC8EN

Abstracts

The 7 major spina bifida in utero markets are expected to exhibit a CAGR of 6.59% during 2024-2034.

The spina bifida in utero market has been comprehensively analyzed in IMARC's new report titled "Spina Bifida In Utero Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Spina bifida in utero refers to a congenital neural tube defect that occurs during early fetal development, where the neural tube, which eventually forms the spinal cord, fails to close completely. This condition leads to incomplete development of the spinal cord and the surrounding vertebrae. The symptoms of the disorder can differ widely, ranging from mild to severe. Common indications include motor and sensory deficits, difficulty walking, bladder and bowel control issues, and, in more severe cases, paralysis and hydrocephalus (accumulation of cerebrospinal fluid in the brain). The intensity of symptoms largely depends on the extent of the spinal cord and nerve involvement. The diagnosis of spina bifida in utero often involves prenatal screening methods, such as ultrasound and maternal serum alpha-fetoprotein (AFP) tests. These investigations can help to identify potential abnormalities in the developing fetus's spine and provide crucial information for early intervention and treatment planning.

The increasing prevalence of mutations or dysfunction in genes like VANGL1, which is implicated in the proper closure of the neural tube, is primarily driving the spina bifida in utero market. In addition to this, the inflating utilization of efficacious medications, such as folic acid supplementation preconception and in early pregnancy, to mitigate the impact and progression of the ailment is also creating a positive outlook for the market. Moreover, the widespread adoption of surgical interventions like in utero

myelomeningocele repair that are designed to minimize neural damage and improve postnatal function is further bolstering the market growth. Apart from this, the rising usage of advanced diagnostic techniques, such as prenatal imaging through ultrasound and maternal serum screening, is acting as another significant growth-inducing factor. These approaches empower healthcare providers with critical insights into the condition's severity, enabling them to formulate comprehensive strategies for optimal care. Additionally, the emerging popularity of multidisciplinary approaches, encompassing physical therapy and assistive devices, to bolster mobility, muscle strength, and overall functionality is also augmenting the market growth. Furthermore, the escalating demand for regenerative medicine, including stem cell therapy and tissue engineering, since they work by harnessing the body's innate healing mechanisms to restore damaged neural tissues, is expected to drive the spina bifida in utero market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the spina bifida in utero market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for spina bifida in utero and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the spina bifida in utero market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the spina bifida in utero market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the spina bifida in utero market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current spina bifida in utero marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

How has the spina bifida in utero market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they

expected to perform till 2034?

What was the country-wise size of the spina bifida in utero market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the spina bifida in utero market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of spina bifida in utero across the seven major markets?

What is the number of prevalent cases (2018-2034) of spina bifida in utero by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of spina bifida in utero by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with spina bifida in utero across the seven major markets?

What is the size of the spina bifida in utero patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of spina bifida in utero?

What will be the growth rate of patients across the seven major markets?

Spina Bifida In Utero: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for spina bifida in utero drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the spina bifida in utero market?

What are the key regulatory events related to the spina bifida in utero market?

What is the structure of clinical trial landscape by status related to the spina bifida in

utero market?

What is the structure of clinical trial landscape by phase related to the spina bifida in utero market?

What is the structure of clinical trial landscape by route of administration related to the spina bifida in utero market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 SPINA BIFIDA IN UTERO - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 SPINA BIFIDA IN UTERO - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 SPINA BIFIDA IN UTERO - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (2018-2034)
 - 7.2.4 Epidemiology by Gender (2018-2034)
 - 7.2.5 Diagnosed Cases (2018-2034)
 - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (2018-2034)
 - 7.3.4 Epidemiology by Gender (2018-2034)
 - 7.3.5 Diagnosed Cases (2018-2034)
 - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (2018-2034)
 - 7.4.4 Epidemiology by Gender (2018-2034)
 - 7.4.5 Diagnosed Cases (2018-2034)
 - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (2018-2034)
 - 7.5.4 Epidemiology by Gender (2018-2034)
 - 7.5.5 Diagnosed Cases (2018-2034)
 - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (2018-2034)
 - 7.6.4 Epidemiology by Gender (2018-2034)
 - 7.6.5 Diagnosed Cases (2018-2034)
 - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (2018-2034)
 - 7.8.4 Epidemiology by Gender (2018-2034)
 - 7.8.5 Diagnosed Cases (2018-2034)
 - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (2018-2034)
 - 7.9.4 Epidemiology by Gender (2018-2034)
 - 7.9.5 Diagnosed Cases (2018-2034)
 - 7.9.6 Patient Pool/Treated Cases (2018-2034)

8 SPINA BIFIDA IN UTERO - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 SPINA BIFIDA IN UTERO - UNMET NEEDS

10 SPINA BIFIDA IN UTERO - KEY ENDPOINTS OF TREATMENT

11 SPINA BIFIDA IN UTERO - MARKETED PRODUCTS

- 11.1 List of Spina Bifida In Utero Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Drug Name – Company Name
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 SPINA BIFIDA IN UTERO - PIPELINE DRUGS

12.1 List of Spina Bifida In Utero Pipeline Drugs Across the Top 7 Markets

12.1.1 Drug Name – Company Name

12.1.1.1 Drug Overview

12.1.1.2 Mechanism of Action

12.1.1.3 Clinical Trial Results

12.1.1.4 Safety and Efficacy

12.1.1.5 Regulatory Status

Kindly note that the complete list of pipeline drugs has been provided in the report.

13. SPINA BIFIDA IN UTERO - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. SPINA BIFIDA IN UTERO – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status

14.2 Drugs by Phase

14.3 Drugs by Route of Administration

14.4 Key Regulatory Events

15 SPINA BIFIDA IN UTERO - MARKET SCENARIO

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Spina Bifida In Utero - Market Size

15.2.1.1 Market Size (2018-2023)

15.2.1.2 Market Forecast (2024-2034)

15.2.2 Spina Bifida In Utero - Market Size by Therapies

15.2.2.1 Market Size by Therapies (2018-2023)

15.2.2.2 Market Forecast by Therapies (2024-2034)

15.3 Market Scenario - United States

15.3.1 Spina Bifida In Utero - Market Size

15.3.1.1 Market Size (2018-2023)

15.3.1.2 Market Forecast (2024-2034)

15.3.2 Spina Bifida In Utero - Market Size by Therapies

15.3.2.1 Market Size by Therapies (2018-2023)

15.3.2.2 Market Forecast by Therapies (2024-2034)

15.3.3 Spina Bifida In Utero - Access and Reimbursement Overview

15.4 Market Scenario - Germany

15.4.1 Spina Bifida In Utero - Market Size

15.4.1.1 Market Size (2018-2023)

15.4.1.2 Market Forecast (2024-2034)

15.4.2 Spina Bifida In Utero - Market Size by Therapies

15.4.2.1 Market Size by Therapies (2018-2023)

15.4.2.2 Market Forecast by Therapies (2024-2034)

15.4.3 Spina Bifida In Utero - Access and Reimbursement Overview

15.5 Market Scenario - France

15.5.1 Spina Bifida In Utero - Market Size

15.5.1.1 Market Size (2018-2023)

15.5.1.2 Market Forecast (2024-2034)

15.5.2 Spina Bifida In Utero - Market Size by Therapies

15.5.2.1 Market Size by Therapies (2018-2023)

15.5.2.2 Market Forecast by Therapies (2024-2034)

15.5.3 Spina Bifida In Utero - Access and Reimbursement Overview

15.6 Market Scenario - United Kingdom

15.6.1 Spina Bifida In Utero - Market Size

15.6.1.1 Market Size (2018-2023)

15.6.1.2 Market Forecast (2024-2034)

15.6.2 Spina Bifida In Utero - Market Size by Therapies

15.6.2.1 Market Size by Therapies (2018-2023)

15.6.2.2 Market Forecast by Therapies (2024-2034)

15.6.3 Spina Bifida In Utero - Access and Reimbursement Overview

15.7 Market Scenario - Italy

15.7.1 Spina Bifida In Utero - Market Size

15.7.1.1 Market Size (2018-2023)

15.7.1.2 Market Forecast (2024-2034)

15.7.2 Spina Bifida In Utero - Market Size by Therapies

15.7.2.1 Market Size by Therapies (2018-2023)

15.7.2.2 Market Forecast by Therapies (2024-2034)

15.7.3 Spina Bifida In Utero - Access and Reimbursement Overview

15.8 Market Scenario - Spain

15.8.1 Spina Bifida In Utero - Market Size

15.8.1.1 Market Size (2018-2023)

15.8.1.2 Market Forecast (2024-2034)

15.8.2 Spina Bifida In Utero - Market Size by Therapies

15.8.2.1 Market Size by Therapies (2018-2023)

15.8.2.2 Market Forecast by Therapies (2024-2034)

- 15.8.3 Spina Bifida In Utero - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Spina Bifida In Utero - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Spina Bifida In Utero - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Spina Bifida In Utero - Access and Reimbursement Overview

16 SPINA BIFIDA IN UTERO - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 SPINA BIFIDA IN UTERO MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 SPINA BIFIDA IN UTERO MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Spina Bifida In Utero Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/S145F0215EC8EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S145F0215EC8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

